Harpoon Therapeutics Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics or view top-rated stocks.

Wall Street analysts have given Harpoon Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Harpoon Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Harpoon Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,960,000 shares, an increase of 69.0% from the June 15th total of 1,160,000 shares. Based on an average daily volume of 318,300 shares, the short-interest ratio is currently 6.2 days. Approximately 9.6% of the shares of the company are sold short.
View Harpoon Therapeutics' Short Interest.

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Harpoon Therapeutics.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its earnings results on Thursday, May, 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. The business earned $9.01 million during the quarter, compared to analyst estimates of $6.80 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 68.36% and a negative net margin of 428.95%.
View Harpoon Therapeutics' earnings history.

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has decreased by 20.4% and is now trading at $10.40.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 1 year target prices for Harpoon Therapeutics' stock. Their forecasts range from $25.00 to $40.00. On average, they anticipate Harpoon Therapeutics' share price to reach $32.88 in the next year. This suggests a possible upside of 216.1% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics or view top-rated stocks among Wall Street analysts.

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Harpoon Therapeutics include Ocugen (OCGN), Krystal Biotech (KRYS), AlloVir (ALVR), ImmunityBio (IBRX), Graphite Bio (GRPH), Vaxcyte (PCVX), Inhibrx (INBX), Agenus (AGEN), Forma Therapeutics (FMTX), Scholar Rock (SRRK), Atara Biotherapeutics (ATRA), Cullinan Oncology (CGEM), Monte Rosa Therapeutics (GLUE), Immunovant (IMVT) and Coherus BioSciences (CHRS).
View all of HARP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HARP stock can currently be purchased for approximately $10.40.

Harpoon Therapeutics has a market capitalization of $338.25 million and generates $17.44 million in revenue each year. The company earns $-49,910,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

Harpoon Therapeutics employs 84 workers across the globe.

The official website for Harpoon Therapeutics is www.harpoontx.com.

Harpoon Therapeutics is headquartered at 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]